Sökning: WFRF:(HOLMBERG E) >
Survival and safety...
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.
-
Coombes, R C (författare)
-
Kilburn, L S (författare)
-
Snowdon, C F (författare)
-
visa fler...
-
Paridaens, R (författare)
-
Coleman, R E (författare)
-
Jones, S E (författare)
-
Jassem, J (författare)
-
Van de Velde, C J H (författare)
-
Delozier, T (författare)
-
Alvarez, I (författare)
-
Del Mastro, L (författare)
-
Ortmann, O (författare)
-
Diedrich, K (författare)
-
Coates, A S (författare)
-
Bajetta, E (författare)
-
- Holmberg, Stig B, 1946 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences
-
Dodwell, D (författare)
-
Mickiewicz, E (författare)
-
Andersen, J (författare)
-
Lønning, P E (författare)
-
Cocconi, G (författare)
-
Forbes, J (författare)
-
Castiglione, M (författare)
-
Stuart, N (författare)
-
Stewart, A (författare)
-
Fallowfield, L J (författare)
-
Bertelli, G (författare)
-
Hall, E (författare)
-
Bogle, R G (författare)
-
Carpentieri, M (författare)
-
Colajori, E (författare)
-
Subar, M (författare)
-
Ireland, E (författare)
-
Bliss, J M (författare)
-
visa färre...
-
(creator_code:org_t)
- 2007
- 2007
- Engelska.
-
Ingår i: Lancet. - 1474-547X. ; 369:9561, s. 559-70
- Relaterad länk:
-
https://gup.ub.gu.se...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- BACKGROUND: Early improvements in disease-free survival have been noted when an aromatase inhibitor is given either instead of or sequentially after tamoxifen in postmenopausal women with oestrogen-receptor-positive early breast cancer. However, little information exists on the long-term effects of aromatase inhibitors after treatment, and whether these early improvements lead to real gains in survival. METHODS: 4724 postmenopausal patients with unilateral invasive, oestrogen-receptor-positive or oestrogen-receptor-unknown breast cancer who were disease-free on 2-3 years of tamoxifen, were randomly assigned to switch to exemestane (n=2352) or to continue tamoxifen (n=2372) for the remainder of a 5-year endocrine treatment period. The primary endpoint was disease-free survival; overall survival was a secondary endpoint. Efficacy analyses were intention-to-treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN11883920. RESULTS: After a median follow-up of 55.7 months (range 0-89.7), 809 events contributing to the analysis of disease-free survival had been reported (354 exemestane, 455 tamoxifen); unadjusted hazard ratio 0.76 (95% CI 0.66-0.88, p=0.0001) in favour of exemestane, absolute benefit 3.3% (95% CI 1.6-4.9) by end of treatment (ie, 2.5 years after randomisation). 222 deaths occurred in the exemestane group compared with 261 deaths in the tamoxifen group; unadjusted hazard ratio 0.85 (95% CI 0.71-1.02, p=0.08), 0.83 (0.69-1.00, p=0.05) when 122 patients with oestrogen-receptor-negative disease were excluded. CONCLUSIONS: Our results suggest that early improvements in disease-free survival noted in patients who switch to exemestane after 2-3 years on tamoxifen persist after treatment, and translate into a modest improvement in overall survival.
Nyckelord
- Aged
- Androstadienes
- adverse effects
- therapeutic use
- Aromatase Inhibitors
- adverse effects
- therapeutic use
- Breast Neoplasms
- drug therapy
- mortality
- pathology
- Disease-Free Survival
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Humans
- Middle Aged
- Neoplasm Recurrence
- Local
- Postmenopause
- Selective Estrogen Receptor Modulators
- adverse effects
- therapeutic use
- Survival Analysis
- Tamoxifen
- adverse effects
- therapeutic use
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
-
Lancet
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- Av författaren/redakt...
-
Coombes, R C
-
Kilburn, L S
-
Snowdon, C F
-
Paridaens, R
-
Coleman, R E
-
Jones, S E
-
visa fler...
-
Jassem, J
-
Van de Velde, C ...
-
Delozier, T
-
Alvarez, I
-
Del Mastro, L
-
Ortmann, O
-
Diedrich, K
-
Coates, A S
-
Bajetta, E
-
Holmberg, Stig B ...
-
Dodwell, D
-
Mickiewicz, E
-
Andersen, J
-
Lønning, P E
-
Cocconi, G
-
Forbes, J
-
Castiglione, M
-
Stuart, N
-
Stewart, A
-
Fallowfield, L J
-
Bertelli, G
-
Hall, E
-
Bogle, R G
-
Carpentieri, M
-
Colajori, E
-
Subar, M
-
Ireland, E
-
Bliss, J M
-
visa färre...
- Artiklar i publikationen
-
Lancet
- Av lärosätet
-
Göteborgs universitet